We studied 53 patients (aged 2 months to 96 years) with scabies treated with 5% phenothrin lotion (SUMITHRIN® Lotion 5%). The patients included 8 infants, 2 children, one pregnant woman, one lactating woman, and 5 with crusted scabies. Of the 53 patients, 33 were treated with phenothrin lotion alone and the remaining 20 with a combination of phenothrin and other scabicides. Fifteen of the 33 (45.5%) treated with phenothrin lotion alone were cured with two applications. Patients with crusted scabies, children, elderly patients, and cases previously treated with topical corticosteroids due to misdiagnosis were treated with 3 to 6 applications of phenothrin. None of the 53 patients showed adverse reactions to the lotion. We concluded that 5% phenothrin lotion is safe and effective in the treatment of scabies, not only in adults, but also in infants and pregnant and lactating women.
A recent deep sequencing study of primary melanomas and their adjacent lesions has identified an intermediate category of melanocytic neoplasia during melanoma progression, characterized by the presence of more than one pathogenic mutation and distinctive histological features, including so-called dysplastic nevus. We report a case of such intermediate melanocytic lesion on the back of a 50-year-old woman. She had a small melanotic macule on her back since early childhood, which had gradually enlarged in the last 10 years. Examination revealed a brownish-black, bell-shaped plaque on the back 15×14 mm in size, with color variegation and a partial irregular, blurred margin. The histopathology showed marked proliferation of melanocytes with slight nuclear atypia present in both basal and mid epidermal layers in continuation with junctional dysplastic nevus. BRAF gene mutation analysis revealed the V600K mutation. We diagnosed this case as a dysplastic nevus evolving into melanoma in situ.